Haleon PLC Sponsored ADR
HLN Healthcare Drug Manufacturers Specialty & Generic
Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024.
Follow HLN
Alert me
Haleon PLC Sponsored ADR (HLN) EBITDA
Haleon PLC Sponsored ADR's EBITDA for fiscal 2025 was $3.7B, up 13.1% from $3.2B in fiscal 2024. Over the past ten years it has ranged from $2.6B (fiscal 2022) to $3.7B (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 3 consecutive fiscal years. Haleon PLC Sponsored ADR ranks 2nd of 80 Drug Manufacturers Specialty & Generic companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $3.7B | 13.06% |
| FY2024 | $3.2B | 12.76% |
| FY2023 | $2.9B | 9.76% |
| FY2022 | $2.6B | (12.96%) |
| FY2021 | $3.0B | 3.54% |
| FY2020 | $2.9B | 10.65% |
| FY2019 | $2.6B | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2024 | $916.9M | 10.39% |
| Mar 2024 | $830.6M | 12.35% |
| Sep 2023 | $739.3M | (58.13%) |
| Jun 2023 | $1.8B | 131.83% |
| 1 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | $8.3B |
| HLN Haleon PLC Sponsored ADR | $4.3B |
| ZTS Zoetis Inc. compare | $4.0B |
| VTRS Viatris Inc. compare | $2.7B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $2.3B |
| UTHR United Therapeutics Corporation compare | $1.4B |
| NBIX Neurocrine Biosciences, Inc. compare | $976.5M |
| ELAN Elanco Animal Health Incorporated compare | $774.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $526.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on HLN
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- Beneish M-score
- The full statement